Member Info for Rebster408

Haha well done Laura

What names did you give to Mark?

You absolute fantasist 😂

Another extension?

When will they ever learn?

Last time I was at school 0.5% of 0 was……er…0

John just spilling the beans here...

its now pretty clear that the change of direction is due to partner/potential licensee demands...

Did John just slip up there...

I'm sure he said 'the diseases our partner companies want to take into P2'...

All looks good to me...

Results to date 'couldn't be better' and a clear timeline into H2 2025

Why is he hiding in the toilets?

Enki

Your a weird one..

your posts change more than the wind...

Regardless of the sp today, 15-20p is giving it away.

fWIW I would hope for at least IPO price @£1.50

The desparation here is so obvious…

I’m not bothered about porky or share if they are one and the same… not interested as it matters not

But PM, Laura and pat… if desperation was an ocean you guys would be the pacific

Cheers H

I’m sure the mist will clear sometime soon and we will see what’s going on and with who

And your second question… although the dates seem out..

Sareum has not provided specific public timelines regarding the start, duration, or expected results for its upcoming long-term toxicology trials for SDC-1801 or SDC-1802. However, based on standard practices in drug development, we can make some educated estimates.

1. When will the long-term toxicology trials begin?

The long-term toxicology trials would likely begin after the completion of the Phase 1 safety trial for SDC-1801, which assesses short-term safety in humans. Since Sareum announced in late 2023 that the Phase 1a trial of SDC-1801 was successfully completed, the company could be planning to initiate long-term toxicology studies soon after, likely in early to mid-2024, before moving into Phase 2 efficacy trials.

2. How long will the trials last?

Long-term toxicology studies typically last 3 to 6 months in animal models, depending on the regulatory requirements and the dosing regimen. Since these studies are designed to evaluate the effects of chronic exposure to the drug, they need to provide sufficient data to support its use over extended periods in humans. In some cases, studies could extend to a year or more, but the standard timeframe is around 6 months.

3. When would final results be expected?

Given that long-term toxicology trials usually last about 6 months, and additional time is needed for data analysis and reporting, we could expect results around late 2024 to early 2025 if the trials begin in early 2024. The completion of these studies is a critical milestone for progressing the drug into Phase 2 trials, where efficacy and safety will be tested in larger patient populations.

Conclusion

• Start of trials: Possibly early to mid-2024.

• Duration: Likely 3-6 months.

• Final results: Expected by late 2024 to early 2025.

These estimates depend on regulatory feedback, preclinical results, and Sareum’s development timeline announcements. Keep an eye on Sareum’s future updates for more precise information.

Fearg in answer to your first question…

While SAR443122 (1802) and SDC-1801, both Sareum’s TYK2/JAK1 inhibitors, share similarities in terms of targeting similar mechanisms in immune response, it is highly likely that 1802 will still need to undergo its own set of safety trials, including Phase 1 clinical trials. Here’s why:

1. Chemical Differences: Even though they are similar, SDC-1801 and SDC-1802 may have different chemical structures or properties, which could result in different pharmacokinetics, metabolism, or safety profiles in humans. Minor differences in drug formulation can cause unexpected safety issues.

2. Disease Target: SDC-1801 is being developed for autoimmune diseases, while SDC-1802 is focused on cancer (potentially targeting hematological malignancies and solid tumors). The patient populations and disease conditions differ significantly, which could impact how the drug behaves and what adverse effects are observed. For example, cancer patients often have compromised immune systems and may react differently to TYK2/JAK1 inhibitors.

3. Regulatory Requirements: Regulatory authorities like the FDA or EMA usually require each drug to be tested independently in clinical trials. The rationale is that even small changes between similar drugs can have significant effects on safety or efficacy. SDC-1802 will likely need to demonstrate a favorable safety profile, particularly because it is targeting cancer patients, who may have a different risk profile than autoimmune patients.

4. Precedent in Drug Development: Even if two drugs are structurally similar, drug developers are typically required to prove that each compound is safe and effective for its intended use. Historical examples show that drugs with seemingly minor differences can perform very differently in clinical settings.

In short, while the success of SDC-1801 in its Phase 1 trials is promising, SDC-1802 will likely need to go through its own set of safety trials to account for its specific application and any potential differences between the two compounds.

Cheers Celtic

I must have missed that.. or old age is starting to kick in!!

just searching for clues and the name didn't seem familiar among the usual suspects.

Interesting days ahead... Here's hoping they are good days...

Boehringer Ingelheim

Exploratory Research: Boehringer Ingelheim has been involved in research on the DDR pathways and potential Chk1 inhibitors, though specific candidates are less publicized.

Anyone come across these before?

Potnak

Using AI is a good shout, as on another board I follow there are a number of questions put into AI which return interesting answers, which in turn feed good discussions...

Enki

ignore Surfie and his sidekick Funny guy...

They're just here to cause mischief so dont feed them or encourage them...

This is a repeat of the last bun fight where porky is repeating himself constantly with his belief that the cash has run out and a raise is imminent.

Then we have the desperate rampers Laura and PM relentlessly pumping this and attacking Porky with abuse.

FWIW I’m also over 99% down here but have to ask… how old are 201 and 401? When was the last time they were actually worked on and developed?

Granted it’s a new BOD and they need a chance but do you really thing 10 year old ‘products’ are going to be effective? And actually make the company money?

Sorry but I’m bring pessimistic and think a raise will come before any kind of deal, and even if there is a deal, given the age and development stage of said products, does anyone really think they are worth multi millions?

Good luck but I’m not holding my breath

I’m still here Laura

And I’m not expecting the deals like many here are.

I remember George saying ‘it **** works!’ So won’t get carried away.

New BOD granted but until there is a RNS stating the deal AND monetary value it’s just words…

Is there a placing due shortly? 🙄

Laura

You are seriously obsessed with Porky - get help.

I dont recall seeing a single post of yours about VAL the company, its issue or outlook.

PM - you just chat 5h1t .. honestly change the record as your desperate pumping is so obvious, try another approach.

Paternospaupaer - you spent how long trawling through Porky's chat history to produce that? Really?

Porky - you are also on repeat, everyone here knows your views so why not just wait until the presentation and begging bowl come out again? would save everyone a lot of grief trawling through these posts...

And as for VAL? Vapourware.. nothing to see here in my opinion other than a lifestyle company...

I've written of my losses and accepted I'll never recover them.. so I'm just sitting back and watching from a distance.

Is potnak also funny guy?

Looks increasingly likely